IT
|
EN
|
FR
|
ES
|
DE
Values
Our identity
Consumer protection
Employees & partners
Mission
Environment
Code of conduct
Whistleblowing
Corporate compliance
Sustainability report
Kip for social
Corporate
Innovative PMI
Nutraceuticals
Profile and organization
Research and development
Company validations
Product validations
Patents
KIP Academy
Investors Relations
Governance
Highlights
Events and Investor day
Corporate events calendar
Financial press releases
Presentations
Shareholders’ Meetings
Financial reports
Analyst coverage
Shareholders Information
IPO
Investor relations contacts
Quality & protection
Raw materials choice
Attention to food intolerances
Study about the packs
Information in braille
Tamper Evident system
Conservation and transportation
The nutraceutic module
Products
All products
Uro-Gynecological Line
Almetax
®
Almetax Easy
®
Ivuxur
®
sachets
Ivuxur
®
tablets
Miledix
®
Xinprox
®
Orthopedic and Fisiatric Line
Dolatrox
®
Milesax
®
Xinepa
®
Xinepa Easy
®
Doltendix
®
KIP
®
Pharmacy
Kip
®
Kit
Other products
Dolatrox hcc
®
Media
News
Press review
Press kit
Contact Media Relations
Contact
For consumers
For doctors
For pharmacies and health stores
For distributors
For other subjects
For investors
Work with us
Where we are
Legal notice
Privacy
E-commerce
Language
Italiano
English
Français
Español
Deutsch
News
News from the world KOLINPHARMA
25/10/2022
- published at 16.47
KOLINPHARMA
®
signs an agreement with ASTAREAL
®
AB for distribution in the Asian market
An important three-year agreement for distribution of products in Mainland China, Hong Kong, Macao and Taiwan
05/08/2021
- published at 16.06
Kolinpharma
®
at VITAFOODS Europe 2021 in Geneva and at CPHI Worldwide 2021 in Milan
KOLINPHARMA
®
strengthens its marketing and brand awareness strategy
26/08/2020
- published at 14.14
KOLINPHARMA
®
expands its product portfolio with IVUXUR
®
TABLETS.
KOLINPHARMA
®
presents the new product IVUXUR
®
TABLETS, which is added to the other 9 patented or patent pending products
16/04/2020
- published at 14.49
KOLINPHARMA
®
:first patent for XINEPA
®
in Israel and fifth outside Italy
Xinepa
®
is a nutraceutical product already in possession of a double patent in Italy
31/03/2020
- published at 11.48
KOLINPHARMA
®
donates a pulmonary ventilator for the hospitals of city of catanzaro to fight COVID 19
KOLINPHARMA
®
supports physicians and health professionals by becoming a partner in the fundraising initiative "Politeama Foundation
10/03/2020
- published at 16.45
KOLINPHARMA
®
obtains the patent in the U.S. of Dolatrox
®
It is the fourth patent that is added to Ivuxur
®
and to the 2 of Xinepa
®
05/02/2018
- published at 09.48
The scientific medical information: an extraordinary job, because it is ethical, scientific and it empathizes with the doctor
KOLINPHARMA always took care about the selection of its collaborators.
05/02/2018
- published at 09.53
Functional Growth: the policy of “internal growth”
KOLINPHARMA wants to give functional growth opportunities to its own collaborators
05/02/2018
- published at 09.58
Marketing: a specific science which studies the market
Kolinpharma completed the company organization, including a Junior Product Manager
09/01/2018
- published at 12.16
KOLINPHARMA
®
in the European research
Since 2017, the company faced an international research.
02/01/2018
- published at 12.15
KOLINPHARMA
®
chooses Hoffmann & Eitle Italia as partner
One of the biggest European law firm specialized in patents, models and design and of all internation industrial protection rights.
02/01/2018
- published at 10.24
A quoted company at AIM, as depositary and logistic: Bomi Group
KOLINPHARMA gave to BOMI Group the storage and the transport of its products to distributors.
02/01/2018
- published at 10.28
Research and Development team (R&D): effectiveness and innovation
The company’s beating heart, the R&D team, is part of the company.
29/12/2017
- published at 10.33
The 231, a model which commit us everyday
All the direct and indirect staff, firm the Company Ethical Code, with consciousness and commitment about what it is necessary follow.
22/12/2016
- published at 14.16
2016: KOLINPHARMA
®
revenue redoubles!
The effort of all, from company heart to sales network, has enabled us to reach the target set at the begin of the year: the revenue doubling, touched 2,5 million in 2016.
> News archive
Media
News
Almetax Easy and tablets
Certified products
Company validations
Consumer Protection
Corporate compliance
Dolatrox
Ivuxur
Milesax
Nutraceuticals
Profile and organization
Research and development
Respect the environment
Xinepa Easy and tablets
Press review
Press Kit
Contact media relations
“Science accuracy and listen to people”
“Science accuracy and listen to people”